| ADMIN | STUDY | CLOSE DATE |
Intergroup Study |
OPEN | COOPGRP | COUNT |
|---|---|---|---|---|---|---|
| BREAST | S2206-Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva | Y | ALLIANCE | 60 | ||
| ECOG-ACRIN | 81 | |||||
| NRG | 49 | |||||
| SWOG | 221 | |||||
| sum | 411 | |||||
| S2212-Breast, TNBC, Neoadj Chemo + Pembro | Y | ALLIANCE | 281 | |||
| ECOG-ACRIN | 283 | |||||
| NRG | 187 | |||||
| SWOG | 901 | |||||
| sum | 1652 | |||||
| CCD | S1703-Met Breast, STM-monitoring v Usual Care | Y | ALLIANCE | 24 | ||
| ECOG-ACRIN | 32 | |||||
| NRG | 24 | |||||
| SWOG | 393 | |||||
| sum | 473 | |||||
| S2417CD-Colrec Surv, Follow-up w/ CTAC site | Y | ALLIANCE | 28 | |||
| ECOG-ACRIN | 12 | |||||
| NRG | 2 | |||||
| SWOG | 82 | |||||
| sum | 124 | |||||
| S2424CD-A-PACT vs SOC for GOC communication | Y | SWOG | 1 | |||
| sum | 1 | |||||
| ERLYTX | S2012-Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo | 09-JUL-26 | T | ALLIANCE | 29 | |
| ECOG-ACRIN | 16 | |||||
| NRG | 13 | |||||
| SWOG | 109 | |||||
| sum | 167 | |||||
| SN2426-cSCC, IC Met/Inop, Amivantamab v Cetuximab | 27-AUG-26 | T | ALLIANCE | 1 | ||
| ECOG-ACRIN | 1 | |||||
| NRG | 1 | |||||
| SWOG | 8 | |||||
| sum | 11 | |||||
| GI | S1922-Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | 15-JUL-26 | N | ALLIANCE | 12 | |
| ECOG-ACRIN | 3 | |||||
| NRG | 3 | |||||
| SWOG | 29 | |||||
| sum | 47 | |||||
| S2104-Panc,Resect High-risk,Postop Adj Chemo vs Obs | Y | ALLIANCE | 13 | |||
| ECOG-ACRIN | 13 | |||||
| NRG | 10 | |||||
| SWOG | 70 | |||||
| sum | 106 | |||||
| S2303-Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo | Y | ALLIANCE | 33 | |||
| ECOG-ACRIN | 12 | |||||
| NRG | 8 | |||||
| SWOG | 62 | |||||
| sum | 115 | |||||
| S2433-PANC, KRAS WT, Met, SOC Chemo +/- Panitumumab | Y | ALLIANCE | 1 | |||
| sum | 1 | |||||
| GU | S1802-Pros, Stg IV, SST ± Surg/RT to Primary Tum | Y | ALLIANCE | 126 | ||
| ECOG-ACRIN | 113 | |||||
| NRG | 130 | |||||
| SWOG | 682 | |||||
| sum | 1051 | |||||
| S1931-RENAL, Stg IV, IO + Nephrectomy. vs IO Only | Y | ALLIANCE | 9 | |||
| ECOG-ACRIN | 19 | |||||
| NRG | 16 | |||||
| SWOG | 116 | |||||
| sum | 160 | |||||
| S1937-Blad, Mets, Eribulin + Gem vs SOC | 13-MAR-26 | N | ALLIANCE | 7 | ||
| ECOG-ACRIN | 22 | |||||
| NRG | 3 | |||||
| SWOG | 100 | |||||
| sum | 132 | |||||
| S2210-Pros, High Risk, BRCA, Neoadj Carbo | Y | SWOG | 6 | |||
| sum | 6 | |||||
| S2419-Renal, adv clear cell, IO +/- Biotx, BIOFRONT | Y | ECOG-ACRIN | 5 | |||
| NRG | 4 | |||||
| SWOG | 15 | |||||
| sum | 24 | |||||
| S2427-Blad, MIBC, RT + Pembrolizumab | Y | ALLIANCE | 13 | |||
| ECOG-ACRIN | 8 | |||||
| NRG | 4 | |||||
| SWOG | 18 | |||||
| sum | 43 | |||||
| LEUK | MM1OA-S03-AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena | Y | ALLIANCE | 6 | ||
| ECOG-ACRIN | 7 | |||||
| NRG | 2 | |||||
| SWOG | 10 | |||||
| sum | 25 | |||||
| MM1YA-S01-AML, High Risk, Age <60, 7+3 vs experimental | Y | ALLIANCE | 14 | |||
| CCTG | 1 | |||||
| ECOG-ACRIN | 19 | |||||
| NRG | 2 | |||||
| SWOG | 48 | |||||
| sum | 84 | |||||
| MYELOMATCH-MSRP for the NCI myeloMATCH Clinical Trials | Y | ALLIANCE | 315 | |||
| CCTG | 82 | |||||
| ECOG-ACRIN | 282 | |||||
| NRG | 57 | |||||
| SWOG | 548 | |||||
| sum | 1284 | |||||
| S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O | Y | ALLIANCE | 58 | |||
| CCTG | 17 | |||||
| ECOG-ACRIN | 21 | |||||
| NRG | 6 | |||||
| SWOG | 106 | |||||
| sum | 208 | |||||
| S2504-Richter Trans., Untreated, R-CHOP +/- Pirto | Y | ECOG-ACRIN | 1 | |||
| sum | 1 | |||||
| LUNG | LUNGMAP-NSCLC, Adv, Master | Y | ALLIANCE | 950 | ||
| ECOG-ACRIN | 418 | |||||
| NRG | 554 | |||||
| SWOG | 2177 | |||||
| sum | 4099 | |||||
| S1800E-Non-Match: Docetaxel + Ramu +/- Cemiplimab | Y | ALLIANCE | 24 | |||
| ECOG-ACRIN | 17 | |||||
| NRG | 14 | |||||
| SWOG | 79 | |||||
| sum | 134 | |||||
| S1900G-EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu | Y | ALLIANCE | 3 | |||
| ECOG-ACRIN | 2 | |||||
| NRG | 3 | |||||
| SWOG | 20 | |||||
| sum | 28 | |||||
| S1900J-MET Amplification: Amivantamab Hyaluronidase | Y | ALLIANCE | 1 | |||
| SWOG | 3 | |||||
| sum | 4 | |||||
| S1900K-MET Exon 14: Tepotinib +/- Ramucirumab | Y | ALLIANCE | 4 | |||
| ECOG-ACRIN | 11 | |||||
| NRG | 1 | |||||
| SWOG | 14 | |||||
| sum | 30 | |||||
| S2409-ESCLC, Durvalumab +/- Biomarker Directed Tx | Y | ECOG-ACRIN | 3 | |||
| NRG | 2 | |||||
| SWOG | 11 | |||||
| sum | 16 | |||||
| S2414-NSCLC, Stg II-IIIB, Durva vs Surveillance | Y | ALLIANCE | 1 | |||
| ECOG-ACRIN | 2 | |||||
| SWOG | 11 | |||||
| sum | 14 | |||||
| LYMPH | S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | 24-APR-26 | N | ALLIANCE | 42 | |
| ECOG-ACRIN | 17 | |||||
| NRG | 7 | |||||
| SWOG | 70 | |||||
| sum | 136 | |||||
| S2114-NHL, Rel/Ref, CD19 CAR-T +/- Consolidation | Y | ALLIANCE | 68 | |||
| ECOG-ACRIN | 22 | |||||
| NRG | 13 | |||||
| SWOG | 143 | |||||
| sum | 246 | |||||
| S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa | Y | ALLIANCE | 7 | |||
| NRG | 5 | |||||
| SWOG | 28 | |||||
| sum | 40 | |||||
| S2308-FL, LTB, Mosunetuzumab vs Rituximab | Y | ALLIANCE | 75 | |||
| ECOG-ACRIN | 62 | |||||
| NRG | 33 | |||||
| SWOG | 244 | |||||
| sum | 414 | |||||
| MMYEL | S1803-MM, Maintenance, Len vs Len/Dara | Y | ALLIANCE | 226 | ||
| CCTG | 21 | |||||
| ECOG-ACRIN | 188 | |||||
| NRG | 117 | |||||
| SWOG | 786 | |||||
| sum | 1338 | |||||
| S2005-WM, Prev. Untreated, I/R or Z v V/R | Y | ALLIANCE | 4 | |||
| ECOG-ACRIN | 24 | |||||
| NRG | 1 | |||||
| SWOG | 8 | |||||
| sum | 37 | |||||
| S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D | Y | ALLIANCE | 16 | |||
| ECOG-ACRIN | 14 | |||||
| NRG | 5 | |||||
| SWOG | 106 | |||||
| sum | 141 | |||||
| S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT | Y | ALLIANCE | 15 | |||
| ECOG-ACRIN | 9 | |||||
| NRG | 2 | |||||
| SWOG | 26 | |||||
| sum | 52 | |||||
| MULT | S2101-Melan or HNSCC, Adv, Cabo + Nivo | Y | ALLIANCE | 22 | ||
| ECOG-ACRIN | 16 | |||||
| NRG | 15 | |||||
| SWOG | 55 | |||||
| sum | 108 | |||||
| PEOLC | S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol | Y | ECOG-ACRIN | 45 | ||
| SWOG | 284 | |||||
| S1501 | Y | ALLIANCE | 40 | |||
| NRG | 30 | |||||
| sum | 399 | |||||
| S2408-Panc Fistula Prevention, Lanreotide | 16-MAR-26 | T | ALLIANCE | 5 | ||
| ECOG-ACRIN | 8 | |||||
| NRG | 2 | |||||
| SWOG | 48 | |||||
| sum | 63 | |||||
| SXQOL | S2013-I-CHECKIT: ICI toxicity risk prediction study | Y | ALLIANCE | 391 | ||
| ECOG-ACRIN | 152 | |||||
| NRG | 316 | |||||
| SWOG | 1771 | |||||
| sum | 2630 | |||||
| S2205-ICE COMPRESS: Reduction of CIPN from Taxanes | Y | ALLIANCE | 96 | |||
| ECOG-ACRIN | 15 | |||||
| NRG | 158 | |||||
| SWOG | 397 | |||||
| sum | 666 | |||||